pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP230845
Phase 2 · other · Amyotrophic lateral Sclerosis
APHP230845 for Amyotrophic lateral Sclerosis is a Phase 2 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP230845
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- other
- Indication
- Amyotrophic lateral Sclerosis
- Status
- active
- Trials
- 1